These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 11353634)

  • 41. Genotypic and phenotypic cross-drug resistance of harboring drug-resistant HIV type 1 subtype B' strains from former blood donors in central Chinese provinces.
    Ma L; Huang J; Xing H; Yuan L; Yu X; Sun J; Huang Y; Qu S; Feng Y; Liao L; Liu S; Shao Y
    AIDS Res Hum Retroviruses; 2010 Sep; 26(9):1007-13. PubMed ID: 20718629
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs.
    de Jong JJ; Goudsmit J; Lukashov VV; Hillebrand ME; Baan E; Huismans R; Danner SA; ten Veen JH; de Wolf F; Jurriaans S
    AIDS; 1999 Jan; 13(1):75-80. PubMed ID: 10207547
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antiviral resistance of biologic HIV-2 clones obtained from individuals on nucleoside reverse transcriptase inhibitor therapy.
    van der Ende ME; Guillon C; Boers PH; Ly TD; Gruters RA; Osterhaus AD; Schutten M
    J Acquir Immune Defic Syndr; 2000 Sep; 25(1):11-8. PubMed ID: 11064499
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A novel genotype encoding a single amino acid insertion and five other substitutions between residues 64 and 74 of the HIV-1 reverse transcriptase confers high-level cross-resistance to nucleoside reverse transcriptase inhibitors. Abacavir CNA2007 International Study Group.
    Rakik A; Ait-Khaled M; Griffin P; Thomas TA; Tisdale M; Kleim JP
    J Acquir Immune Defic Syndr; 1999 Oct; 22(2):139-45. PubMed ID: 10843527
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Emerging trends of drug-resistant HIV-1 among drug-treated patients in former blood donors in Hubei, China: a three-year surveillance from 2004 to 2006.
    Gong J; Wang XQ; Tong X; Shen XH; Yang RG
    Virol Sin; 2011 Dec; 26(6):386-92. PubMed ID: 22160938
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A rapid non-culture-based assay for clinical monitoring of phenotypic resistance of human immunodeficiency virus type 1 to lamivudine (3TC).
    García Lerma J; Schinazi RF; Juodawlkis AS; Soriano V; Lin Y; Tatti K; Rimland D; Folks TM; Heneine W
    Antimicrob Agents Chemother; 1999 Feb; 43(2):264-70. PubMed ID: 9925516
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Genotypic and phenotypic analysis of a novel 15-base insertion occurring between codons 69 and 70 of HIV type 1 reverse transcriptase.
    Lobato RL; Kim EY; Kagan RM; Merigan TC
    AIDS Res Hum Retroviruses; 2002 Jul; 18(10):733-6. PubMed ID: 12167282
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A 21-base pair insertion/duplication at codon 69 of the HIV type 1 reverse transcriptase in a patient undergoing multiple nucleoside therapy.
    Harrigan PR; Mo T; Hirsch J; Brumme ZL; McKenna P; Bacheler L
    AIDS Res Hum Retroviruses; 2007 Jul; 23(7):895-9. PubMed ID: 17678473
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Genotypic and phenotypic changes during culture of a multinucleoside-resistant human immunodeficiency virus type 1 strain in the presence and absence of additional reverse transcriptase inhibitors.
    Shafer RW; Winters MA; Iversen AK; Merigan TC
    Antimicrob Agents Chemother; 1996 Dec; 40(12):2887-90. PubMed ID: 9124861
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance.
    Larder BA; Bloor S; Kemp SD; Hertogs K; Desmet RL; Miller V; Sturmer M; Staszewski S; Ren J; Stammers DK; Stuart DI; Pauwels R
    Antimicrob Agents Chemother; 1999 Aug; 43(8):1961-7. PubMed ID: 10428920
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Structural dynamics and susceptibility of anti-HIV drugs against HBV reverse transcriptase.
    Kammarabutr J; Mahalapbutr P; Okumura H; Wolschann P; Rungrotmongkol T
    J Biomol Struct Dyn; 2021 Apr; 39(7):2502-2511. PubMed ID: 32308149
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Evaluation of the consistency of three methods for testing HIV-1 genotype drug resistance].
    Li J; Jiang Y; Lü C; Wang J; Yao J
    Zhonghua Yu Fang Yi Xue Za Zhi; 2013 Nov; 47(11):1050-5. PubMed ID: 24507237
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical correlates and molecular basis of HIV drug resistance.
    Wainberg MA; Gu Z; Gao Q; Arts E; Geleziunas R; Bour S; Beaulieu R; Tsoukas C; Singer J; Montaner J
    J Acquir Immune Defic Syndr (1988); 1993; 6 Suppl 1():S36-46. PubMed ID: 7678865
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy.
    Lin PF; Samanta H; Rose RE; Patick AK; Trimble J; Bechtold CM; Revie DR; Khan NC; Federici ME; Li H
    J Infect Dis; 1994 Nov; 170(5):1157-64. PubMed ID: 7963708
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phenotypic assays and sequencing are less sensitive than point mutation assays for detection of resistance in mixed HIV-1 genotypic populations.
    Van Laethem K; Van Vaerenbergh K; Schmit JC; Sprecher S; Hermans P; De Vroey V; Schuurman R; Harrer T; Witvrouw M; Van Wijngaerden E; Stuyver L; Van Ranst M; Desmyter J; De Clercq E; Vandamme AM
    J Acquir Immune Defic Syndr; 1999 Oct; 22(2):107-18. PubMed ID: 10843523
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Machine learning aided multiscale modelling of the HIV-1 infection in the presence of NRTI therapy.
    Tunc H; Sari M; Kotil S
    PeerJ; 2023; 11():e15033. PubMed ID: 37020854
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Performance of the Affymetrix GeneChip HIV PRT 440 platform for antiretroviral drug resistance genotyping of human immunodeficiency virus type 1 clades and viral isolates with length polymorphisms.
    Vahey M; Nau ME; Barrick S; Cooley JD; Sawyer R; Sleeker AA; Vickerman P; Bloor S; Larder B; Michael NL; Wegner SA
    J Clin Microbiol; 1999 Aug; 37(8):2533-7. PubMed ID: 10405396
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Diversity and complexity of HIV-1 drug resistance: a bioinformatics approach to predicting phenotype from genotype.
    Beerenwinkel N; Schmidt B; Walter H; Kaiser R; Lengauer T; Hoffmann D; Korn K; Selbig J
    Proc Natl Acad Sci U S A; 2002 Jun; 99(12):8271-6. PubMed ID: 12060770
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A comparative analysis of HIV drug resistance interpretation based on short reverse transcriptase sequences versus full sequences.
    Steegen K; Bronze M; Van Craenenbroeck E; Winters B; Van der Borght K; Wallis CL; Stevens W; Rinke de Wit TF; Stuyver LJ;
    AIDS Res Ther; 2010 Oct; 7():38. PubMed ID: 20950432
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Risk factors and outcomes for the Q151M and T69 insertion HIV-1 resistance mutations in historic UK data.
    Stirrup OT; Dunn DT; Tostevin A; Sabin CA; Pozniak A; Asboe D; Cox A; Orkin C; Martin F; Cane P; ;
    AIDS Res Ther; 2018 Apr; 15(1):11. PubMed ID: 29661246
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.